Bayer ordered to pay $332 million in Roundup cancer trial
Reuters
Published Oct 31, 2023 23:46
Updated Nov 01, 2023 01:05
(Reuters) -A California jury on Tuesday found Bayer (ETR:BAYGN) liable in a case brought by a man who claimed his cancer was due to exposure to the company's Roundup weed killer, and ordered it to pay $332 million in damages.
The verdict includes $7 million in compensatory damages and $325 million in punitive damages awarded to plaintiff Mike Dennis, who was diagnosed at age 51 with a form of non-Hodgkin lymphoma, according to a spokesperson for the company.
The punitive damage award is almost certain to be reduced sharply, as the U.S. Supreme Court has found that punitive damages should be less than 10 times the compensatory damages in virtually all cases.
The jury sided with Bayer on two of four legal claims in the case, the spokesperson said, finding that while the company had failed to warn of Roundup's risks, it had not been negligent and the product was not defectively designed.
The company said in a statement that it has "strong arguments on appeal to get this unfounded verdict overturned and the unconstitutionally excessive damage award eliminated or reduced, given that there were significant and reversible legal and evidentiary errors made during this trial."
A lawyer for Dennis did not immediately respond to a request for comment.
This marks the third trial loss for Bayer this month, after being hit by a $175 million verdict and a $1.25 million verdict in two separate Roundup trials. Before that, it had won nine consecutive trials over similar claims.
Roundup-related lawsuits have dogged Bayer since it acquired the brand as part of its $63 billion purchase of Monsanto (NYSE:MON) in 2018. The company settled most Roundup claims against it in 2020 for up to $10.9 billion, but still faces close to 40,000 Roundup-related cases.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.